Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonard Presta

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Opinion in Structural Biology|September 2, 2003
Antibody engineering for therapeuticsLeonard Presta
Nature Biotechnology|January 11, 2007
Evolving an anti-toxin antibodyLeonard Presta
Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.
Journal of Molecular Biology|July 31, 2003
Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulationCharles Eigenbrot, Y Gloria Meng, Rajeswari Krishnamurthy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2003
Design, construction, and in vitro analyses of multivalent antibodiesKathy Miller, Gloria Meng, Jun Liu, et al.
The Journal of Clinical Investigation|May 4, 2006
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisYi Chen, Claire L Langrish, Brent McKenzie, et al.
Molecular Cancer Therapeutics|October 3, 2023
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive CancersNeil A O'Brien, Martina S J McDermott, Jun Zhang, et al.
Molecular Cancer Therapeutics|August 12, 2005
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibodyYan Wang, Judith Hailey, Denise Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2023
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid TumorsMartina S J McDermott, Neil A O'Brien, Benjamin Hoffstrom, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Opinion in Structural Biology|September 2, 2003
Antibody engineering for therapeuticsLeonard Presta
Nature Biotechnology|January 11, 2007
Evolving an anti-toxin antibodyLeonard Presta
Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.
Journal of Molecular Biology|July 31, 2003
Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulationCharles Eigenbrot, Y Gloria Meng, Rajeswari Krishnamurthy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2003
Design, construction, and in vitro analyses of multivalent antibodiesKathy Miller, Gloria Meng, Jun Liu, et al.
The Journal of Clinical Investigation|May 4, 2006
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisYi Chen, Claire L Langrish, Brent McKenzie, et al.
Molecular Cancer Therapeutics|October 3, 2023
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive CancersNeil A O'Brien, Martina S J McDermott, Jun Zhang, et al.
Molecular Cancer Therapeutics|August 12, 2005
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibodyYan Wang, Judith Hailey, Denise Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2023
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid TumorsMartina S J McDermott, Neil A O'Brien, Benjamin Hoffstrom, et al.
Pageof 1